AnaptysBio Inc (ANAB) - Net Assets
Based on the latest financial reports, AnaptysBio Inc (ANAB) has net assets worth $12.75 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($329.68 Million) and total liabilities ($316.94 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore ANAB current and non-current assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $12.75 Million |
| % of Total Assets | 3.87% |
| Annual Growth Rate | 58.77% |
| 5-Year Change | -89.56% |
| 10-Year Change | -5.24% |
| Growth Volatility | 1113.25 |
AnaptysBio Inc - Net Assets Trend (2013–2025)
This chart illustrates how AnaptysBio Inc's net assets have evolved over time, based on quarterly financial data. Check AnaptysBio Inc tangible equity quality to evaluate the tangible quality of the company's equity base.
Annual Net Assets for AnaptysBio Inc (2013–2025)
The table below shows the annual net assets of AnaptysBio Inc from 2013 to 2025. For live valuation and market cap data, see AnaptysBio Inc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $37.21 Million | -47.49% |
| 2024-12-31 | $70.87 Million | -19.56% |
| 2023-12-31 | $88.10 Million | -66.39% |
| 2022-12-31 | $262.10 Million | -26.46% |
| 2021-12-31 | $356.43 Million | -10.16% |
| 2020-12-31 | $396.73 Million | -2.04% |
| 2019-12-31 | $405.01 Million | -16.73% |
| 2018-12-31 | $486.37 Million | +58.13% |
| 2017-12-31 | $307.58 Million | +683.29% |
| 2016-12-31 | $39.27 Million | -7.25% |
| 2015-12-31 | $42.34 Million | +606.44% |
| 2014-12-31 | $5.99 Million | +4033.10% |
| 2013-12-31 | $145.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to AnaptysBio Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 72376800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $28.00K | 0.08% |
| Other Comprehensive Income | $-24.00K | -0.06% |
| Other Components | $809.76 Million | 2176.20% |
| Total Equity | $37.21 Million | 100.00% |
AnaptysBio Inc Competitors by Market Cap
The table below lists competitors of AnaptysBio Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jiangyin Jianghua Microelectronics Materials Co Ltd
SHG:603078
|
$1.58 Billion |
|
NORINCO International Cooperation Ltd
SHE:000065
|
$1.58 Billion |
|
Jiangsu New Energy Development Co Ltd
SHG:603693
|
$1.58 Billion |
|
ManpowerGroup Inc
NYSE:MAN
|
$1.58 Billion |
|
Zen Technologies Limited
NSE:ZENTEC
|
$1.58 Billion |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321
|
$1.58 Billion |
|
Argan SA
PA:ARG
|
$1.58 Billion |
|
Bestway Marine & Energy Technology Co Ltd
SHE:300008
|
$1.58 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AnaptysBio Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 70,868,000 to 37,210,000, a change of -33,658,000 (-47.5%).
- Net loss of 13,232,000 reduced equity.
- Share repurchases of 68,626,000 reduced equity.
- New share issuances of 14,261,000 increased equity.
- Other comprehensive income decreased equity by 329,000.
- Other factors increased equity by 34,268,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-13.23 Million | -35.56% |
| Share Repurchases | $68.63 Million | -184.43% |
| Share Issuances | $14.26 Million | +38.33% |
| Other Comprehensive Income | $-329.00K | -0.88% |
| Other Changes | $34.27 Million | +92.09% |
| Total Change | $- | -47.49% |
Book Value vs Market Value Analysis
This analysis compares AnaptysBio Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 44.95x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 409.37x to 44.95x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $0.13 | $53.36 | x |
| 2014-12-31 | $2.42 | $53.36 | x |
| 2015-12-31 | $16.60 | $53.36 | x |
| 2016-12-31 | $14.89 | $53.36 | x |
| 2017-12-31 | $15.55 | $53.36 | x |
| 2018-12-31 | $19.71 | $53.36 | x |
| 2019-12-31 | $14.97 | $53.36 | x |
| 2020-12-31 | $14.53 | $53.36 | x |
| 2021-12-31 | $12.99 | $53.36 | x |
| 2022-12-31 | $9.31 | $53.36 | x |
| 2023-12-31 | $3.27 | $53.36 | x |
| 2024-12-31 | $2.50 | $53.36 | x |
| 2025-12-31 | $1.19 | $53.36 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AnaptysBio Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -35.56%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -5.64%
- • Asset Turnover: 0.64x
- • Equity Multiplier: 9.79x
- Recent ROE (-35.56%) is above the historical average (-337.46%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -3824.14% | -101.13% | 1.40x | 26.99x | $-5.56 Million |
| 2014 | 3.87% | 1.46% | 0.63x | 4.18x | $-367.30K |
| 2015 | -12.77% | -30.76% | 0.31x | 1.33x | $-9.64 Million |
| 2016 | -10.85% | -25.53% | 0.27x | 1.58x | $-8.19 Million |
| 2017 | -9.78% | -300.70% | 0.03x | 1.07x | $-60.83 Million |
| 2018 | -12.68% | -1233.12% | 0.01x | 1.05x | $-110.29 Million |
| 2019 | -24.03% | -1216.70% | 0.02x | 1.07x | $-137.84 Million |
| 2020 | -5.02% | -26.57% | 0.18x | 1.05x | $-59.60 Million |
| 2021 | -16.22% | -91.49% | 0.10x | 1.80x | $-93.44 Million |
| 2022 | -49.11% | -1251.33% | 0.02x | 2.33x | $-154.93 Million |
| 2023 | -185.71% | -953.66% | 0.04x | 5.13x | $-172.43 Million |
| 2024 | -204.93% | -159.10% | 0.19x | 6.83x | $-152.32 Million |
| 2025 | -35.56% | -5.64% | 0.64x | 9.79x | $-16.95 Million |
Industry Comparison
This section compares AnaptysBio Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,074,129
- Average return on equity (ROE) among peers: -103.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AnaptysBio Inc (ANAB) | $12.75 Million | -3824.14% | 24.86x | $1.58 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $143.70 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $335.61 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $30.03 Million | -30.65% | 0.08x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $5.82 Million | -168.16% | 1.54x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $17.90 Million | -209.78% | 2.98x | $10.89 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $479.08 Million | -51.18% | 0.13x | $3.66 Billion |
About AnaptysBio Inc
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial… Read more